Novartis AG (NVS)

Add a New Bears Reason Company: Novartis AG (NVS) Current price: Headline: (100 character max) Analysis: Cancel 25% agree 4 votes   Diabetes drug delayed 1-2 years while clinical trials are conducted Top Contributor: Adam Farren | Created when NYSE:NVS was $55.45 | Edit | History Galvus, a diabetes drug that was expected to be a high volume seller (billions) for Novartis, has been delayed one to two years while further clinical trials are conducted. When it enters the market, Galvus will have to compete against Merck's already-established diabetes medication Januvia. (100 character max) Cancel 33% agree 6 votes   Standard & Poors downgraded Novartis from a "AAA" rating Top Contributor: Bret Holmes | Created when NYSE:NVS was $47.48 | Edit | History Standard & Poor’s cut its AAA rating on Novartis AG (NVS) to AA- after the firm announced it would finance its acquisition of Alcon Inc. (ACL) with new debt, Bloomberg News reported. "Novartis’ lack of commitment to the former AAA rating is demonstrated" by the use of debt to fund the Alcon purchase, S&P credit analyst Olaf Toelke said in the statement announcing the downgrade. "This action is a marked deviation from the group’s former conservative financial policy." (100 character max) Cancel 0% agree 2 votes   Patent on key ingredients in Lotrel will expire within the year Created when NYSE:NVS was $55.45 | Edit | History The patent on key ingredients in Lotrel will expire within the year and generic competitors are expected to enter the market. (100 character max) Cancel 0% agree 2 votes   FDA increasing regulations on contact with physicians Created when NYSE:NVS was $55.45 | Edit | History Over the past few years there have been increasing federal and state regulations on the pharmaceutical industry in the way it contacts physicians and advertises. This limits sales and building of brand loyalty and could hurt Novartis and other pharmaceuticals’ profits. (100 character max) Cancel

Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.